Compare ADMA Biologics Inc (ADMA) vs Barrick Gold Corp (B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Barrick Gold Corp — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Barrick Gold Corp trades at $40.13 (market cap $68.49B). The key difference: Barrick Gold Corp is far larger — about 31.4× ADMA Biologics Inc's market cap, and Barrick Gold Corp pays a 1.71% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | B | |
|---|---|---|
Market Cap | $2.18B | $68.49B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $52.97 |
52-Week Low | $7.60 | $22.83 |
Enterprise Value | $2.25B | $66.08B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Barrick Mining (B) trades at $43.69, up 5.49% in 24 hours, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a $1.95 billion settlement with Newmont, and a robust cash flow trend highlight operational strength. The stock is near its consensus price target of $50.17, supported by a 66.67% analyst buy rating.
The outlook is positive due to earnings growth, favorable valuations, and strategic initiatives like the North American IPO. Risks include gold price volatility and execution of expansion plans. Upside potential exists if the company maintains its earnings momentum and capitalizes on gold market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
